JP2014524748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524748A5 JP2014524748A5 JP2014520658A JP2014520658A JP2014524748A5 JP 2014524748 A5 JP2014524748 A5 JP 2014524748A5 JP 2014520658 A JP2014520658 A JP 2014520658A JP 2014520658 A JP2014520658 A JP 2014520658A JP 2014524748 A5 JP2014524748 A5 JP 2014524748A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen
- antigen binding
- seq
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 41
- 108091000831 antigen binding proteins Proteins 0.000 claims 41
- 238000006467 substitution reaction Methods 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 241000269435 Rana <genus> Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 claims 1
- 230000006916 protein interaction Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1112429.4A GB201112429D0 (en) | 2011-07-19 | 2011-07-19 | Antigen-binding proteins with increased FcRn binding |
| GB1112429.4 | 2011-07-19 | ||
| PCT/EP2012/064129 WO2013011076A2 (en) | 2011-07-19 | 2012-07-19 | Antigen-binding proteins with increased fcrn binding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524748A JP2014524748A (ja) | 2014-09-25 |
| JP2014524748A5 true JP2014524748A5 (enExample) | 2015-08-13 |
Family
ID=44586854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520658A Pending JP2014524748A (ja) | 2011-07-19 | 2012-07-19 | ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130243764A1 (enExample) |
| EP (2) | EP2734548B1 (enExample) |
| JP (1) | JP2014524748A (enExample) |
| KR (1) | KR20140054085A (enExample) |
| CN (1) | CN103748110A (enExample) |
| AU (1) | AU2012285786B2 (enExample) |
| BR (1) | BR112014000341A2 (enExample) |
| CA (1) | CA2841105A1 (enExample) |
| CL (1) | CL2014000134A1 (enExample) |
| CO (1) | CO6862106A2 (enExample) |
| CR (1) | CR20140029A (enExample) |
| DO (1) | DOP2014000007A (enExample) |
| EA (1) | EA201391789A1 (enExample) |
| ES (1) | ES2600854T3 (enExample) |
| GB (1) | GB201112429D0 (enExample) |
| MA (1) | MA35345B1 (enExample) |
| MX (1) | MX2014000739A (enExample) |
| PE (1) | PE20141660A1 (enExample) |
| PH (1) | PH12014500167A1 (enExample) |
| SG (1) | SG10201601154QA (enExample) |
| WO (1) | WO2013011076A2 (enExample) |
| ZA (1) | ZA201400062B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140186361A1 (en) | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR20160105535A (ko) | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| EP2931749B1 (fr) * | 2012-12-17 | 2019-04-24 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| WO2014114651A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| BR112015017307A2 (pt) * | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| ES2688726T5 (es) * | 2013-07-19 | 2022-06-27 | Hexal Ag | Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| AU2014337263B2 (en) * | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| PL2946765T3 (pl) * | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| EP3250598A1 (en) * | 2015-01-28 | 2017-12-06 | Mabxience S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| EP3411401A1 (en) | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| CN109071631B (zh) | 2016-03-14 | 2023-07-14 | 奥斯陆大学 | 具有改变的FcRn结合的工程化免疫球蛋白 |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| AU2017255077B2 (en) | 2016-04-28 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| CA3027018A1 (en) | 2016-07-29 | 2018-02-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| US11286295B2 (en) * | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| US10980881B2 (en) | 2017-01-11 | 2021-04-20 | Celltrion Inc. | Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine |
| EP3569615A4 (en) * | 2017-01-13 | 2020-07-29 | Hanx Biopharmaceutics, Inc | PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JP7209298B2 (ja) | 2017-03-31 | 2023-01-20 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物 |
| EP3665195A4 (en) * | 2017-08-11 | 2021-05-19 | Research Development Foundation | MANIPULATED ANTIBODY FC VARIANTS FOR INCREASED SERUM HALF-VALUE |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| CA3071236A1 (en) | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient |
| KR20260090008A (ko) | 2017-11-01 | 2026-06-16 | 추가이 세이야쿠 가부시키가이샤 | 생물 활성이 저하된 항체 배리언트 및 아이소폼 |
| BR112020015006A2 (pt) * | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| MX2021010611A (es) * | 2019-03-05 | 2021-11-12 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Aves con genoma editado. |
| CN114466663B (zh) | 2019-07-25 | 2026-01-02 | 建新公司 | 以FcRn拮抗剂治疗抗体介导的障碍的方法 |
| CN115770291A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用 |
| CN115770292A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 |
| CN115772227A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用 |
| EP4434517A4 (en) * | 2021-11-30 | 2025-06-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-sost antibody pharmaceutical composition and use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE239041T1 (de) * | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| EP1355919B1 (en) * | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| EP2684895A1 (en) * | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
| CN101848936B (zh) | 2007-08-20 | 2017-05-03 | 葛兰素集团有限公司 | 生产方法 |
| TW200944231A (en) * | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| KR101616758B1 (ko) * | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| EP2225276B1 (en) * | 2007-12-31 | 2014-04-23 | Bayer Intellectual Property GmbH | Antibodies to tnf alpha |
| FR2934599B1 (fr) | 2008-07-29 | 2012-12-21 | Arkema France | Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations |
| RU2481824C2 (ru) * | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
| CA2753287A1 (en) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| NZ594514A (en) * | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| EA201190273A1 (ru) * | 2009-05-28 | 2012-12-28 | Глаксо Груп Лимитед | Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз |
| WO2011074965A1 (en) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物 |
-
2011
- 2011-07-19 GB GBGB1112429.4A patent/GB201112429D0/en not_active Ceased
-
2012
- 2012-07-19 MX MX2014000739A patent/MX2014000739A/es unknown
- 2012-07-19 EP EP12738101.0A patent/EP2734548B1/en active Active
- 2012-07-19 AU AU2012285786A patent/AU2012285786B2/en not_active Ceased
- 2012-07-19 CA CA2841105A patent/CA2841105A1/en not_active Abandoned
- 2012-07-19 CN CN201280034887.5A patent/CN103748110A/zh active Pending
- 2012-07-19 SG SG10201601154QA patent/SG10201601154QA/en unknown
- 2012-07-19 EP EP15197750.1A patent/EP3009450A1/en not_active Withdrawn
- 2012-07-19 KR KR1020147004161A patent/KR20140054085A/ko not_active Withdrawn
- 2012-07-19 BR BR112014000341A patent/BR112014000341A2/pt not_active IP Right Cessation
- 2012-07-19 PH PH1/2014/500167A patent/PH12014500167A1/en unknown
- 2012-07-19 ES ES12738101.0T patent/ES2600854T3/es active Active
- 2012-07-19 JP JP2014520658A patent/JP2014524748A/ja active Pending
- 2012-07-19 EA EA201391789A patent/EA201391789A1/ru unknown
- 2012-07-19 US US13/988,400 patent/US20130243764A1/en not_active Abandoned
- 2012-07-19 WO PCT/EP2012/064129 patent/WO2013011076A2/en not_active Ceased
- 2012-07-19 PE PE2014000086A patent/PE20141660A1/es not_active Application Discontinuation
-
2014
- 2014-01-06 ZA ZA2014/00062A patent/ZA201400062B/en unknown
- 2014-01-17 CL CL2014000134A patent/CL2014000134A1/es unknown
- 2014-01-17 DO DO2014000007A patent/DOP2014000007A/es unknown
- 2014-01-20 CR CR20140029A patent/CR20140029A/es unknown
- 2014-01-21 CO CO14011137A patent/CO6862106A2/es not_active Application Discontinuation
- 2014-02-12 MA MA36748A patent/MA35345B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6746564B2 (ja) | Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用 | |
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| RU2015130100A (ru) | TNF-альфа антиген-связывающие белки | |
| JP2022513420A5 (enExample) | ||
| JP2013544492A5 (enExample) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2018521691A5 (enExample) | ||
| JP2014508511A5 (enExample) | ||
| CA2792740A1 (en) | Antibodies with ph dependent antigen binding | |
| RU2011101969A (ru) | Антитела к человеческому интерлейкину-20 | |
| JP7689116B2 (ja) | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 | |
| JP2022518530A (ja) | 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体 | |
| JP2023109973A (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用 | |
| CA3213751A1 (en) | Fusion proteins, pharmaceutical compositions, and therapeutic applications | |
| TW202243689A (zh) | 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥 | |
| JP2022522815A5 (enExample) | ||
| KR20230044448A (ko) | 항-pd-1 항체 약학적 조성물 및 이의 용도 | |
| AU2019269131B2 (en) | Antibodies against LIF and dosage forms thereof | |
| EP4190352B1 (en) | Formulation of novel bispecific anti-cd3/cd20 polypeptide complex | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| JP2023527918A5 (enExample) | ||
| JP2025526418A (ja) | 二重特異性抗ｃ－Ｋｉｔ及び抗ＣＤ２０３Ｃ抗原結合分子ならびにそれらの使用 | |
| US20240327483A1 (en) | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications | |
| TW202124432A (zh) | 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法 |